KEYTRUDA Padcev MIBC Survival: New Era in Treat...

By HEOR Staff Writer

March 2, 2026

KEYTRUDA Padcev MIBC Survival Breakthrough in Cisplatin-Eligible Patients KEYTRUDA Padcev MIBC Survival benefits shone in the Phase 3 KEYNOTE-B15 trial, where...
Infarmed Regulatory Activity: January 2026 Highlights and Impacts on Market A...
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
Economic Impact of Industry Clinical Trials in Europe
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
Enhancing Systematic Reviews: AI Literature Review Integration for Efficiency...
Administrative Court Error Complicates Infarmed Vaccine Data Transparency
EMA Executive Director Recruitment: Leading the Future of Medicines Regulation
Biopharma Ecosystem Competitiveness: Post-COVID Challenges and Opportunities
EMA Validation of ENHERTU Breast Cancer Treatment for Post-Neoadjuvant Therapy
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...
Enhancing Safety and Performance: The Role of EU Medical Device Panels
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implica...